|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Secondary acquired mutant EGFR (L858R-T790M) overexpressed NSCLC forms one of the prevalent form of resistant NSCLC.
|
31078412 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The L858R one-point mutation in exon 21 in EGFR is the most prevalent in NSCLC.
|
30593826 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free survival (PFS) versus standard-of-care (SoC) EGFR-TKI (gefitinib or erlotinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced non-small cell lung cancer (NSCLC).
|
30659024 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Adult patients with stage IIIB/IV EGFR Mut+ NSCLC (exon 19 deletion or exon 21 L858R mutation) who had received first-line systemic therapy between 2011 and 2016 were included.
|
30608948 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study potentially offers an innovative therapeutic avenue for the NSCLC with L858R/T790M-mutated EGFR.
|
30237564 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
|
30030903 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation).
|
29737372 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).
|
29151359 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.
|
29568384 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC.
|
29174310 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Previously, we detected circulating tumor DNA that contained two EGFR mutations (p.L858R and exon19 del) in plasma of patients with late-stage non-small-cell lung carcinoma (NSCLC) using the electric field-induced release and measurement (EFIRM) platform.
|
30309763 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
|
30471829 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
As a proof of concept study, we used the lab-on-a-disc to isolate cfDNA from patients with non-small cell lung cancer and successfully detected epidermal growth factor receptor gene mutations (L858R, T790M) during targeted drug therapy.
|
29658031 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Thirty-six tissue samples from non-small-cell lung cancer (NSCLC) patients were detected by our method and 14/36 tissues gave EGFR L858R mutation-positive results, whereas ARMS-PCR just identified 12 of L858R mutant samples.
|
30128808 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study was conducted to compare the efficacy of a combination of icotinib and chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)-sensitive mutations and to analyze the curative effect of different treatments on different genetic mutations (EGFR 19 exon deletion and L858R mutation) in a real-life setting.
|
29731642 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The presence of a deletion mutation in exon 19 or L858R point mutation in the EGFR kinase domain has been shown to cause enhanced efficacy of inhibitor treatment in patients with NSCLC.
|
29369805 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletion and L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are both common mutations that predict a good response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
|
26967328 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The primary endpoint was the odds ratio (OR) of T790M mutation in NSCLC co-existing with L858R mutation and 19 del upon resistance to first-generation EGFR-TKIs.A random effects model was used.
|
29850136 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib.
|
29514601 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
E746-A750 deletion and L858R mutations were screened in 50 unselected NSCLC formalin-fixed paraffin-embedded (FFPE) tissue samples.
|
30092812 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery.
|
29571986 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors.
|
30145586 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Targeting the 3 most common epidermal growth factor receptor mutations (exon 19 deletion, T790M, L858R) found in non-small cell lung cancer (NSCLC), we achieved >20-fold increases in AF and detected mutations by use of qPCR at an AF of 0.1%.
|
29038154 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Although almost all common EGFR mutations, such as exon 19 deletions and the L858R point mutation in exon 21, are sensitive to EGFR-tyrosine kinase inhibitor (TKI) therapies, NSCLC driven by EGFR exon 20 insertion mutations is associated with poor clinical outcomes due to dose-limiting toxicity, demonstrating the need for a novel therapy.
|
29748209 |
2018 |